BSEBoard Meeting6d ago · 10 Aug 2026, 10:31 am

Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve unaudited standalone and ....

Kilitch Drugs India Ltd · 524500

✦ AI SummaryResults

Kilitch Drugs India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Kilitch Drugs India Ltd - 524500 - Board Meeting Intimation for Considering And Approval Of Unaudited Financial Results For The Quarter Ended 30Th June, 2026

Attachments (1)

📄

858656df-965e-49ee-afd4-59799b491f61.pdf

pdf

Download →
View document text
Kilitch Drugs (India) Ltd. 10 August, 2026 To, To, The Manager - Corporate Relationship The Manager - Corporate Compliance Dept. National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot No.C-1, P. J. Towers, Dalal Street G Block, BKC, Bandra (E), Fort, Mumbai - 400 001 Mumbai 400 051 Scrip Code: BSE - 524500 Scrip Code: NSE - KILITCH Sub: Intimation of the Board Meeting Dear Sir, Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the meeting of the Board of Directors of the Company will be held on Thursday, 13"* August, 2026 inter-alia to consider and approve the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30 June, 2026. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2! April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2™ April, 2019 issued by NSE and Company’s code of conduct for Prevention of Insider Trading, the Trading Window has been closed with effect from 1%‘ July, 2026 and will re-open 48 hours after said financial results are disclosed to the Stock Exchanges. We request you to kindly take the same on record and acknowledge the receipt. Thanking you, Yours Faithfully, For Kilitch Drugs (India) Limited Mukund Mehta Managing Director DIN: 00147876 (FES fae sIees SpeanO Wer te @ie ‘ )‘ , BG Sy SS INDIA 13485:2003 © WHO CERTIFIED Sma Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. e Tel.: +91-22-6121 4100 « Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. « CIN: L24239MH1992PLC066718 « Tel.: +91-22-6299 6300 « Fax : +91-22-2768 0912 « E-mail : info@kilitch.com « Website : www.kilitch.com